Drug reference
delgocitinib
Pan-JAK inhibitor · Immunosuppressant
Pan-JAK inhibitorImmunosuppressant
CDSCO approved
EXCRETION
—
not curated
INTERACTIONS
—
none in our sources
PREGNANCY
—
not curated
Mechanism
Not yet extracted
Contraindications
- nonuse during breastfeeding
- concurrent use of live vaccines
Side effects
Common
thrombocytopeniaanemianeutropeniaincreased risk of infections (upper respiratory, sinus, common cold, hepatitis c virus)
Serious
- increased risk of serious bacterial, fungal, viral, and opportunistic infections leading to hospitalization or death
- higher rate of all-cause mortality, including sudden cardiovascular death
- higher rate of certain cancers
- higher rate of thrombosis, cardiovascular death, myocardial infarction, and stroke
Related guidelines
Ask House about delgocitinib
Continue into a citation-backed clinical answer with the drug context already attached.
Textbook-sourced·Sources: Goodman & Gilman 14e·Updated: 2026-05-10